We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
On Sep 20, 2016, we issued an updated research report on California-based Align Technology Inc. (ALGN - Free Report) , a developer of aligner therapy, intra-oral scanners and CAD/CAM (computer-aided design and computer-aided manufacturing) digital services. Currently, Align carries a Zacks Rank #2 (Buy).
Persistent strong Invisalign volume growth across the company’s entire customer base primarily continues to drive results for Align.
In the last reported quarter, geographically, Align was successful in delivering double-digit sales growth in North America as well as overseas. In North America, the company witnessed continued increase in utilization among its orthodontist customers that reached record levels in both ortho and GP channels.
In the international space too, the company delivered a strong performance across all countries. In the EMEA region, growth was led by Spain, France and the Netherlands. In Asia Pacific, strong expansion was observed in China, Japan, South Asia and Taiwan.
However, a vast majority of Align’s total net revenue is highly dependent on the sale of its Invisalign System and the same trend is expected to continue at least in the near future. Management fears that if consumer demand for Align’s orthodontic services somehow declines or consumers become averse to adopt Invisalign as rapidly as expected, the company’s business may be severely affected.
We are concerned about the ongoing economic uncertainty too, which casts a gloom on Align’s dental procedures as well. The competitive landscape also remains a major headwind.
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Align Technology: Invisalign Growth Continues Globally
On Sep 20, 2016, we issued an updated research report on California-based Align Technology Inc. (ALGN - Free Report) , a developer of aligner therapy, intra-oral scanners and CAD/CAM (computer-aided design and computer-aided manufacturing) digital services. Currently, Align carries a Zacks Rank #2 (Buy).
Persistent strong Invisalign volume growth across the company’s entire customer base primarily continues to drive results for Align.
In the last reported quarter, geographically, Align was successful in delivering double-digit sales growth in North America as well as overseas. In North America, the company witnessed continued increase in utilization among its orthodontist customers that reached record levels in both ortho and GP channels.
In the international space too, the company delivered a strong performance across all countries. In the EMEA region, growth was led by Spain, France and the Netherlands. In Asia Pacific, strong expansion was observed in China, Japan, South Asia and Taiwan.
However, a vast majority of Align’s total net revenue is highly dependent on the sale of its Invisalign System and the same trend is expected to continue at least in the near future. Management fears that if consumer demand for Align’s orthodontic services somehow declines or consumers become averse to adopt Invisalign as rapidly as expected, the company’s business may be severely affected.
We are concerned about the ongoing economic uncertainty too, which casts a gloom on Align’s dental procedures as well. The competitive landscape also remains a major headwind.
Key Picks in the Sector
Some other top-ranked medical stocks worth a look are Antares Pharma Inc. , Derma Sciences Inc. and Merit Medical Systems, Inc. (MMSI - Free Report) . All these stocks hold a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>